Navigation Links
InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
Date:2/20/2009

BRISBANE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release fourth quarter and full-year 2008 financial results on Thursday, February 26, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 86755415. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 86755415.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Announces Issuance of U.S. Patent for ITMN-191
2. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
3. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
4. InterMune to Present at J.P. Morgan Healthcare Conference
5. InterMune to Present at Deutsche Bank Biotech Boston Confab
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Release Third Quarter 2008 Financial Results on November 6
8. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
9. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
10. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
11. InterMune to Present at Canaccord Adams Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... Wisconsin (PRWEB) , ... July 25, 2017 , ... ... the food and beverage industry, offers Citri-Fi® 125. This natural citrus fiber is used ... thicken and extend real tomato in sauces, condiments and spreads. Today, more than ever, ...
(Date:7/25/2017)... Canaan, CT (PRWEB) , ... July 25, 2017 ... ... sustainable products that enhance the microbiome and improve efficiency of livestock farming while ... announced that it has licensed additional intellectual property from Cornell University. , ...
(Date:7/24/2017)... , July 24, 2017 Intralytix, Inc. announced ... from Lesaffre, a French family group. This investment marks ... to develop and commercialize bacteriophage-based products, for various benefits ... interest. As ... designs manufactures and markets innovative solutions for baking, food ...
(Date:7/24/2017)... Springs, FL (PRWEB) , ... ... ... Chief Strategic Analyst, Kenny Soulstring, today announced that the stock market news ... specializing in risk assessment diagnostic testing that screens and identifies exposure, progression ...
Breaking Biology Technology:
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):